BEAM Beam Therapeutics Inc.

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

$86.17  +0.18 (0.20%)
As of 06/23/2021 15:59:56 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1997
Outstanding shares:  62,578,078
Average volume:  615,388
Market cap:   $5,376,708,462
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    07373V105
ISIN:        US07373V1052
Sedol:      BK6L288
Valuation   (See tab for details)
PE ratio:   -14.71
PB ratio:   12.45
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy